The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...
Health-care companies ticked up as traders rotated back into higher risk sectors. Eli Lilly shares rose after the maker of weight-loss drugs filed for U.S. Food and Drug Administration approval of a ...
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase III Attain-Maintain trial with ...
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and ...
Stocktwits on MSN
Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics
The company studied Orforglipron for weight maintenance over 52 weeks in patients who were on 72 weeks of popular injectable ...
Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual ...
According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.
Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback